Disease · MONDO_0006033
diffuse intrinsic pontine glioma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. diffuse intrinsic pontine glioma. Diseases, record MONDO_0006033. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006033
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs80
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| DORDAVIPRONE | CHEMBL4297310 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| NIMOTUZUMAB | CHEMBL2108359 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| VALPROIC ACID | CHEMBL109 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ANTINEOPLASTON A10 | CHEMBL1980825 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LOMUSTINE | CHEMBL514 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PHENYLACETIC ACID | CHEMBL1044 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 80
See all 80 drugsTargets150
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 5 | Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 vaccine antigen; Epidermal growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 5 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| HDAC1 | Histone deacetylase | 3 | Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor | Phase 2 | https://conductscience.org/library/genes/3065 | Drugs and targets |
| HDAC2 | Histone deacetylase | 3 | Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor | Phase 2 | https://conductscience.org/library/genes/3066 | Drugs and targets |
| HDAC3 | Histone deacetylase | 3 | Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor | Phase 2 | https://conductscience.org/library/genes/8841 | Drugs and targets |
| HDAC6 | Histone deacetylase | 3 | Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor | Phase 2 | https://conductscience.org/library/genes/10013 | Drugs and targets |
| TUBA1A | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
1 to 10 of 150
See all 150 targetsTrials85
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03130959 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | Phase 2 | 166 | 2021-04-01 | Various Advanced Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01189266 | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Phase 1/2 | 79 | 2020-03-03 | Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma | VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | Phase 1/2 | 57 | 2024-10-09 | Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma | CEMIPLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01182350 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 2 | 53 | 2019-09-04 | Diffuse Intrinsic Pontine Glioma | BEVACIZUMAB, ERLOTINIB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02717455 | Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma | Phase 1 | 53 | 2024-04-25 | Glioma | PANOBINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03257631 | A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | Phase 2 | 53 | 2019-12-10 | Central Nervous System Neoplasms, Medulloblastoma | POMALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02960230 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | Phase 1/2 | 50 | 2025-01-22 | Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | HILTONOL, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | Phase 1 | 46 | 2024-01-03 | Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma | ADAVOSERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | Phase 2 | 43 | 2018-07-20 | Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors | IMETELSTAT SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT01751308 | Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors | Phase 1/2 | 39 | 2016-08-12 | Malignant Solid Tumor - Malignant Nervous System Neoplasm | CABAZITAXEL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 85
See all 85 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| RB+ High Grade Glioma vs Non-Biopsied Diffuse Instrinsic Pontine Glioma: Number of Patients Alive at One Year | 0 of 1 | 8 of 9 | 10 | NCT02607124 | Trial comparisons |
| Arm 1 vs Arm 2: deaths from any cause | 2 of 3 | 1 of 2 | 5 | NCT03330197 | Trial comparisons |
| Arm 1 vs Arm 2: serious adverse events | 1 of 3 | 1 of 2 | 5 | NCT03330197 | Trial comparisons |
Papers from its trials85
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006033
GET https://conductscience.org/api/diseases/v1/MONDO_0006033/drugs?page=2